Goldman Sachs analyst Robert Jones initiated coverage of PRA Health Sciences with a Buy rating and $126 price target. The stock has underperformed the clinical contract research origination group and S&P 500 by 12% and 6% year-to-date, respectively, amid concerns of slowing clinical revenue growth and execution risks within the company's data solutions segment, Jones tells investors in a research note. However, he sees an attractive entry point at current share levels. PRA Health's revenue growth is poised to reaccelerate through the second half of 2019 and 2020 as burn rates stabilize, strategic partnerships ramp, and comps ease, says the analyst.